Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Migraine therapeutics differentially modulate the CGRP pathway
Minoti Bhakta, Trang Vuong, Tetsuya Taura, et al.
Cephalalgia (2021) Vol. 41, Iss. 5, pp. 499-514
Open Access | Times Cited: 80

Showing 26-50 of 80 citing articles:

Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany
Armin Scheffler, P Wenzel, Merle Bendig, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
CGRP and the Calcitonin Receptor are Co-Expressed in Mouse, Rat and Human Trigeminal Ganglia Neurons
Tayla A. Rees, Andrew F. Russo, Simon J. O’Carroll, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 21
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
Mária Dux, Birgit Vogler, A.G. Kühn, et al.
Cells (2022) Vol. 11, Iss. 11, pp. 1768-1768
Open Access | Times Cited: 20
Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD
Andrew M. Strassman, Agustín Melo-Carrillo, Timothy T. Houle, et al.
Cephalalgia (2022) Vol. 42, Iss. 9, pp. 933-943
Open Access | Times Cited: 19
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine
Andrew Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 3, pp. 322-332
Open Access | Times Cited: 12
Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
Michał Fila, Jan Chojnacki, Piotr Sobczuk, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 289-289
Open Access | Times Cited: 11
Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families
Manuel Lisardo Sánchez, Francisco D. Rodríguez, Rafael Coveñas
Cancers (2023) Vol. 15, Iss. 6, pp. 1694-1694
Open Access | Times Cited: 11
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Zoe Tasma, Michael L. Garelja, Aqfan Jamaluddin, et al.
Pharmacology & Therapeutics (2025), pp. 108846-108846
Open Access
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 8, pp. 867-885
Open Access | Times Cited: 17
Antinociceptive Effects of an Anti-CGRP Antibody in Rat Models of Colon-Bladder Cross-Organ Sensitization
Ehsan Mohammadi, Casey O. Ligon, Kimberly D. Mackenzie, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 387, Iss. 1, pp. 4-14
Open Access | Times Cited: 10
Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors
Michael L. Garelja, Tyla I. Alexander, Amy Bennie, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 1, pp. 142-161
Open Access | Times Cited: 9
Associations of type 2 diabetes and the risk of migraine in Chinese populations
Jielong Wu, Jie Fang, Xiaodong Yuan, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 2, pp. 101518-101518
Closed Access | Times Cited: 3
Therapeutic approaches for UCPPS management: research advances, experimental targets, and future directions
Salman Ashraf, Taylor Clarkson, Anna P. Malykhina
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 390, Iss. 2, pp. 222-232
Open Access | Times Cited: 3
Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
Michael Nsaka, Armin Scheffler, Sebastian Wurthmann, et al.
Brain and Behavior (2022) Vol. 12, Iss. 7
Open Access | Times Cited: 15
Effect of heavy metals in fish reproduction: A review
T. Bera, S.V. Kumar, Mrs Sinmayee Kumari Devi, et al.
Journal of Environmental Biology (2022) Vol. 43, Iss. 5, pp. 631-642
Open Access | Times Cited: 14
Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief
Luigi Francesco Iannone, Romina Nassini, Riccardo Patacchini, et al.
Temperature (2022) Vol. 10, Iss. 1, pp. 50-66
Open Access | Times Cited: 13
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor
Sanne Hage la Cour, Kiki Juhler, Lisette J. A. Kogelman, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Cryo-EM Structure of the Human Amylin 1 Receptor in Complex with CGRP and Gs Protein
Jianjun Cao, Matthew J. Belousoff, Radostin Danev, et al.
Biochemistry (2024) Vol. 63, Iss. 9, pp. 1089-1096
Open Access | Times Cited: 2
Pituitary cyclase‐activating polypeptide targeted treatments for the treatment of primary headache disorders
Nazia Karsan, Lars Edvinsson, László Vécsei, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 7, pp. 1654-1668
Open Access | Times Cited: 2
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review
Abimael González‐Hernández, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2024)
Closed Access | Times Cited: 2
First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients
Yang Zhao, Xiaodan Wang, Mengyue Niu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Differential expression of components of the CGRP-receptor family in human coronary and human middle meningeal arteries: functional implications
Tessa de Vries, Dennis J.L.G. Schutter, Antoon van den Bogaerdt, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research
Tayla A. Rees, Alejandro Labastida‐Ramírez, Eloísa Rubio‐Beltrán
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 10, pp. 651-663
Open Access | Times Cited: 6

Scroll to top